Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination

Lavanya Visvabharathy[1*¶], Barbara Hanson[1,3], Zachary Orban[1], Patrick H. Lim[1], Nicole Palacio[2], Rishi Jain[1], Eric Michael Liotta[1], Pablo Penaloza-MacMaster[2], Igor J. Koralnik[1*]

[1]Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA

[2]Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago IL 60611 USA

[3]Rush Medical College, Chicago IL 60612 USA

*Corresponding authors: Igor J. Koralnik, M.D.: igor.koralnik@northwestern.edu;
Lavanya Visvabharathy, Ph.D: lavanya.visvabharathy@northwestern.edu
¶ Lead contact: Lavanya Visvabharathy, Ph.D

Summary

The high prevalence of post-acute sequelae of SARS-CoV-2 infection (PASC) is a significant health concern. In particular, virus-specific immunity in patients who suffer from chronic neurologic symptoms after mild acute COVID remain poorly understood. Here, we report that neuro-PASC patients have a specific signature composed of humoral and cellular immune responses that are biased towards different structural proteins compared to healthy COVID convalescents. Interestingly, the severity of cognitive deficits or quality of life markers in neuro-PASC patients are associated with reduced effector molecule expressionn in memory T cells. Furthermore, we demonstrate that T cell responses to SARS-CoV-2 mRNA vaccines are aberrantly elevated in longitudinally sampled neuro-PASC patients compared with healthy COVID convalescents. These data provide a framework for the rational design of diagnostics and predictive biomarkers for long-COVID disease, as well as a blueprint for improved therapeutics.

Keywords: COVID-19 immunity, T cell memory, neuro-PASC, long-COVID, vaccine-induced immunity

Introduction

SARS-CoV-2 is the causative agent of a worldwide pandemic that started in Wuhan, China in December, 2019. There have been more than 200 million cases and over 4 million deaths globally attributable to COVID-19 disease (Center, 2021). Although highly effective vaccines are now used to prevent severe disease and death caused by SARS-CoV-2, long-term sequelae of SARS-CoV-2 infection are increasingly becoming an important medical concern.

SARS-CoV-2 infection is associated with presentations ranging from asymptomatic carriage to severe multi-organ dysfunction (Li et al., 2020; Liguori et al., 2020; Syed et al., 2020). Globally, the estimated fatality rate following SARS-CoV-2 infection is approximately 1-2%, but not all patients recover to their baseline states (Higgins et al., 2020). "Long COVID" affects an estimated 10-40% of all infected people and includes symptoms persisting more than 28 days after diagnosis of SARS-CoV-2 infection, termed "post-acute sequelae of SARS-CoV-2 infection" or PASC (Ladds et al., 2020; Vehar et al., 2021). Greater than two-thirds of hospitalized COVID-19 patients experience ongoing fatigue, breathlessness, and psychiatric issues such as post-traumatic stress disorder (PTSD) 4-8 weeks after discharge (Halpin et al., 2021). However, the vast majority of people with COVID experience mild disease not requiring hospitalization, and more than half of these have symptoms persisting more than 4 months after acute infection (Petersen et al., 2020). Many people who survived Middle-East respiratory virus (MERS) and the original SARS-CoV pandemic also experienced PTSD and neurological impairments up to 3.5 years after acute infection (Ahmed et al., 2020; Lam et al., 2009). More recent studies on recovered COVID-19 patients showed significant cognitive deficits in attention, working memory, and emotional processing months after acute infection had resolved (Hampshire, 2021). Here, we focus on a cohort of mostly non-hospitalized long-COVID patients

presenting with neurological symptoms ("neuro-PASC") who exhibit a reduction in quality of life with regards to cognitive and fatigue parameters (Graham et al., 2021).

Numerous studies suggest that a robust T cell response is necessary for viral clearance in infected individuals. In particular, $CD4^+$ T cell responses directed against the Spike protein were found in 100% of healthy COVID convalescents, while 70% displayed Spike-specific $CD8^+$ T cell responses (Grifoni et al., 2020). Another study found that memory T cells cross-reactive to SARS-CoV-2 nucleocapsid (N) protein persisted in people exposed to SARS-CoV up to 17 years after the epidemic of 2003 (Le Bert et al., 2020). Post-mortem autopsies of COVID-19 patients have shown that innate immune cells but not lymphocytes are enriched in lung infiltrate, and that these patients exhibit impaired germinal center formation in lung draining lymph nodes (Duan et al., 2020). Additional studies have shown that $CD8^+$ T cell depletion after SARS-CoV-2 infection of rhesus macaques impairs anamnestic responses, suggesting a role for T cell memory in long-term immunity to SARS-CoV-2 infection (McMahan et al., 2021).

Most studies on T cell responses to SARS-CoV-2 have focused on acutely symptomatic individuals. However, adaptive immune responses in patients who remain chronically symptomatic remain largely unexplored. Our studies indicate that neuro-PASC patients ("CN") had hypo-functional Ag-specific CD8+ T cell memory responses SARS-CoV-2 compared with healthy convalescents ("CC") and enhanced reactivity to N and M proteins compared with CC subjects. The severity of cognitive deficits and quality of life markers were associated with enhanced polarization in cytolytic granule expression in memory T cell subsets. Finally, we demonstrate that T cell responses to SARS-CoV-2 vaccination are more robust and display aberrant kinetics in neuro-PASC patients compared with control groups. Together, these data demonstrate a wide-scale dysfunction in SARS-CoV-2 T cell memory in neuro-PASC long-

74 hauler patients, with important implications for both appropriate diagnostic and vaccination

75 strategies.

Results

Clinical characteristics of neuro-PASC patients

We enrolled a total of 111 participants prior to SARS-CoV-2 vaccination drawn from the neuro-COVID-19 outpatient clinic at Northwestern Memorial Hospital or from the surrounding Chicago area. This included 56 neuro-PASC "CN" patients (confirmed RT-PCR+ or anti-SARS-CoV-2 Spike IgG+) meeting Infectious Disease Society of America clinical criteria for COVID-19 starting after February 2020 and had neurologic symptoms lasting at least 6 weeks post-infection, as previously reported (Graham et al., 2021). Among those, 48 (86%) were never hospitalized for pneumonia or hypoxemia. We additionally recruited 24 healthy COVID convalescents without lasting symptoms (RT-PCR+ or seropositive for anti- SARS-CoV-2 Spike RBD IgG, "CC"); and 31 healthy controls who were RT-PCR- and seronegative for SARS-CoV-2 Spike-IgG ("HC"; study description in Fig. 1A).

CN patients displayed a constellation of neurological symptoms similar to those previously reported by our group and in other studies (Fig. 1B). In addition, we utilized standardized methods to quantify their quality of life and cognitive disturbances relative to healthy convalescents. Results from the patient reported outcomes information system (PROMIS-57) survey (Tang et al., 2019) showed that CN patients scored significantly lower on physical function and higher on anxiety, depression, pain and other metrics compared with CC subjects or the national average (Fig. 1C). NIH toolbox tests administered to CN patients to assess their cognitive function (Weintraub et al., 2013) showed CN patients had significantly lower T scores in the attention module, which was indicative of cognitive dysfunction relative to the national average (Fig. 1D).

98 *Neuro-PASC is associated with a distinct immunodominance hierarchy.*

99 To determine whether neuro-PASC included alterations in the magnitude and/or
100 specificity of Ag-specific T cell responses in CN patients, we performed ELISPOT for SARS-
101 CoV-2-specific T cells. PBMC from each subject were cultured in the presence of peptide pools
102 derived from spike (S), nucleocapsid (N), or membrane (M) proteins of SARS-CoV-2 (Fig. S1).
103 The magnitude and specificity of both IFN-γ and IL-2 responses to S sub-pools were similar
104 between CN and CC subjects (Fig. 2A-B). However, CN subjects produced high levels of IFN-γ
105 against all sub-pools of N and M proteins, while CC subjects had a specificity for the N1 pool
106 and lower responses against all M pools (Fig. 2C-D), indicative of different immunodominance
107 hierarchies between groups. No significant differences were found in IL-2 production, and
108 healthy controls exhibited some response to N pools likely caused by cross-reactivity with
109 endemic coronaviruses (Fig. 2E-F). Antibody titers against the Spike receptor-binding domain
110 (RBD) did not differ between CN and CC groups (Fig. 2G). Interestingly, high IgG titers did not
111 correlate with the magnitude of the IFN-γ T cell response against S2 or S3 peptide pools
112 comprising the 2 halves of the Spike RBD (Fig. S2).

113 *$CD4^+$ Tfh cells display opposing reactivity to SARS-CoV-2 N- and M-proteins in neuro-PASC vs.*
114 *healthy COVID convalescents*

115 RNA-Seq analysis of $CD4^+$ T cells from hospitalized and non-hospitalized COVID-19
116 patients showed that severe disease is associated with elevated $CD4^+$ T follicular helper (Tfh)
117 proportions relative to patients with mild disease (Meckiff et al., 2020). We sought to determine
118 whether Tfh responses (gating in Fig. S3) that prime antibody production from plasma B cells
119 could similarly differentiate neuro-PASC CN patients from CC individuals. Immunophenotyping
120 showed that there were no differences in total percentages of T cell subsets, including Tfh cells,

121 between groups (Fig. S4). The activation-induced marker (AIM) assay has been previously used
122 to detect TCR-mediated activation of T cells (Grifoni et al., 2020) and we used this method to
123 investigate Tfh cell activation (gating for Tfh cells in Fig. S3). N protein-specific
124 $CD134^{+}CD137^{+}$ (AIM^{+}) CD4 Tfh cells were significantly elevated in CN compared with CC
125 subjects, while the opposite trend was observed in M protein-specific activation (Fig. 3A-B). No
126 differences were seen in Tfh activation between CN and CC groups across Spike peptide pools
127 (Fig. 3B). The magnitude of N- and M-specific Tfh cell activation did not correlate with the time
128 since acute infection in either CN or CC patients (Fig. 3C-D) despite reports showing that
129 antibody titers against N protein decrease rapidly post-infection (Van Elslande et al., 2021)
130 which would presumably lead to decreased N-specific Tfh cell activation over time. N-specific
131 IgG titers were significantly elevated in CN compared with CC subjects (Fig. 3E), consistent
132 with the enhanced N-specific $CD4^{+}$ Tfh cell activation shown in 3B. Similar to Tfh cells, there
133 was no correlation between anti-N IgG titers and time post-symptom onset for either CN or CC
134 subjects (Fig. S5A). Studies have shown that IgG titers against N protein decline to undetectable
135 levels in 40% of COVID convalescents within 4 months (Muecksch et al., 2021). We largely did
136 not observe this decline in CN patients despite collecting their blood samples an average of 193
137 days post-symptom onset (Fig. 1B).

138 *$CD4^{+}$ T cell polyfunctionality to Spike protein differs in neuro-PASC vs. healthy COVID*
139 *convalescents*

140 Cytotoxic $CD4^{+}$ T cells acquire the ability to produce cytolytic granules upon activation
141 with cognate viral antigen (Goubard et al., 2015; Sledzinska et al., 2020). Viral infections
142 specifically induce expansion of the memory $CD4^{+}$ T effector memory cells re-expressing
143 CD45RA (TEMRA) population that secrete copious amounts of cytolytic granules upon antigen

144 encounter (Tian et al., 2017). We therefore investigated whether Ag-specific production of
145 multiple granzymes and cytokines in $CD4^+$ T cells were altered between groups. While CN and
146 HC groups maintained polyfunctionality and polarization, CC subjects had significantly more
147 polyfunctional $CD4^+$ T cells producing granzymes A, B, and M after Spike pool stimulation
148 (category 2 in yellow, Fig. 3F). A heatmap quantifying this effect showed that CC had a 2-fold
149 elevation in category 2 effector molecules over CN subjects (Fig. 3G). This data suggests that
150 cytotoxic responses to Spike protein in $CD4^+$ T cells from healthy COVID-19 convalescents
151 significantly differ from those experiencing chronic neurologic symptoms.

152 *$CD8^+$ memory T cell functionality in neuro-PASC patients*

153 $CD8^+$ memory T cells are crucial for protection from recurrent viral infections (Mockus
154 et al., 2019). Studies have shown that memory $CD8^+$ cells can persist for several years after
155 patient exposure to SARS-CoV (Chen et al., 2005) and that acute mild disease induces stronger
156 Ag-specific $CD8^+$ memory responses than severe disease (Peng et al., 2020). However, little is
157 known about whether $CD8^+$ memory differs in neuro-PASC long-haulers vs. healthy COVID
158 convalescents months after acute infection resolves. To address this, we probed the dynamics of
159 $CD8^+$ TEM, TCM, and TEMRA activation in CN, CC, and HC subjects. $CD8^+$ TEM were
160 significantly activated by various S, N, and M peptide pools in CC subjects while remaining
161 relatively quiescent after antigen stimulation in CN patients (Fig. 4A-B). $CD8^+$ TEMRA are
162 terminally differentiated memory cells with distinct transcriptional programs that respond
163 quickly to viral infections (Tian et al., 2019). Total percentages of $CD8^+$ TEMRA cells were
164 significantly elevated in CN compared with CC and HC groups (Fig. 4C), but despite their
165 increased numbers, $CD8^+$ TEMRA cells were less activated by the S3/4 peptide pool in CN

166 patients and showed a trend towards decreased activation after N pool stimulation compared with
167 CC subjects (Fig. 4D-E).

168 Similarly, antigen stimulation resulted in altered cytokine polarization in $CD8^+$ T cell
169 subsets in CN and CC groups. Effector molecule production in $CD8^+$ T cells was similar across
170 groups in the unstimulated condition, despite showing some statistically significant differences in
171 perforin production (Fig. S6B). However, stimulation with the S3/4 pool induced greater TNF-α
172 production in the CC group while CN patients had enhanced IL-6 production to the same
173 stimulus (Fig. 4F). S pool stimulation also induced $CD8^+$ TEMRA cells from the CC group to
174 produce elevated levels of granzymes, which was not seen in CN or HC groups (Fig. 4G, black
175 lines), demonstrating that $CD8^+$ T cell subsets display decreased functionality in CN vs. CC
176 patients after stimulation.

177 *Impaired cognition and decreased quality of life metrics correlate with distinct patterns of*
178 *polyfunctionality in memory T cell subsets*

179 Having shown that Tfh and T cell memory responses differed between patient groups,
180 we next sought to probe whether within-group differences in T cell responses correlated with
181 various clinical measures in CN patients. We found a significant positive correlation between the
182 magnitude of IFN-γ production to N protein and higher pain interference scores (Fig. 5A). There
183 was also a trend towards a positive correlation between high scores for depression and the
184 magnitude of the N-specific T cell response (Fig. 5B). To look at associations between clinical
185 parameters and T cell activation, we separated T scores from NIH Toolbox or PROMIS-57
186 measurements (Fig. 1C-D) into quartiles and only the lowest and highest groups (Q1 vs. Q4)
187 were used for analysis (Fig. S7A, red boxes). CN subjects reporting high (Q4) pain interference
188 scores produced significantly less granzyme A or B and more IL-6 than those with low scores

189 (Fig. 5C-D) from $CD8^+$ T cells after S pool stimulation. Further, patients reporting low
190 depression scores had highly polyfunctional Spike-specific $CD8^+$ TEM, while those reporting
191 high levels of depression had TEM producing ~3-fold higher granzymes A, B, and M alone
192 (category 2; Fig. 5E, F). The severity of cognitive impairment could also be significantly
193 correlated with T cell responses. Q1 patients scoring low on executive function tests had $CD8^+$
194 TCM polarized towards granzymes A, B, M and perforin production (category 1), while those in
195 Q4 were biased to produce granzymes A, B, and perforin (Fig. 5G-H). Similar analyses were
196 performed for other $CD8^+$ and $CD4^+$ memory T cell subsets, and significant differences by
197 quartile were also found in correlations with depression, processing speed, working memory, and
198 global pain (Fig. S7B-K). These data show that the severity of cognitive deficits or quality of life
199 measures can be significantly correlated with differences in SARS-CoV-2-specific memory T
200 cell function.

201 *SARS-CoV-2 vaccination induces sustained elevation in Spike-specific IFN-γ responses in neuro-*
202 *PASC but not healthy COVID convalescents*

203 SARS-CoV-2 mRNA vaccines have been proven to be highly effective against
204 contracting infection in the short-term in both clinical trials and in real-world settings (Haas et
205 al., 2021; Polack et al., 2020). However, neither clinical trials nor field studies specifically
206 characterized the vaccine-induced immune response in long-COVID patients, and it is similarly
207 unknown whether vaccination can ameliorate long-haul symptoms. One prospective study
208 showed that vaccination did not significantly worsen symptoms in 22 patients with long-COVID
209 (Arnold et al., 2021), but also did not provide evidence to show any decrease in symptoms. To
210 address how vaccine-induced immunity evolves over time in neuro-PASC long-haulers, we
211 conducted a longitudinal vaccine study assessing Spike-specific antibody and T cell responses

212 over the course of 6 months post-vaccination (study design and patient demographics in Fig. 6A-
213 B). While this study is ongoing, we report data from the first 4 months comparing responses in
214 CN, CC, and HC subjects (n for each group per study visit shown in Fig. S8). Vaccination with
215 either Pfizer or Moderna mRNA vaccines induced robust SARS-CoV-2 Spike RBD IgG titers in
216 all groups tested by 3 weeks post-2nd dose, with the highest titers found in CN patients. Antibody
217 titers were at similar levels in all groups by 3 months post-1st dose, but trended higher in CN than
218 in HC subjects at visit (V)4 (Fig. 6C). In parallel, we measured Spike-specific T cell responses in
219 study subjects. The magnitude and kinetics of the T cell response in CC and HC subjects were
220 similar and peaked at V3. However, CN patients had significantly elevated Spike-specific T cell
221 responses compared with either HC or CC groups at V2 after the vaccination boost (Fig. 6D;
222 individual pool data shown in Fig. S9). IFN-γ-specific T cell responses remained high at 4
223 months post-vaccination in CN patients while not significantly differing from pre-vaccination
224 levels in both CC and HC subjects. To our knowledge, these are the first data that longitudinally
225 compare the T cell response to vaccination in neuro-PASC patients with healthy COVID
226 convalescents and unexposed individuals.

227 Overall, our study demonstrates that neuro-PASC patients have elevated IFN-γ responses
228 to N and M proteins, enhanced Ag-specific activation of Tfh cells, sustained anti-N IgG
229 production, and deficient activation of multiple CD8^{+} memory T cell subsets compared with
230 healthy COVID-19 convalescents. There were also correlations between the severity of cognitive
231 deficits or quality of life impairments and Ag-specific cytokine signatures (Fig. 5, S7).
232 Importantly, vaccination resulted in sustained enhancements in the magnitude of Spike-specific
233 T cell responses in neuro-PASC patients vs. all other groups, regardless of prior COVID
234 exposure. Together, we show that CN patients exhibit a large-scale dysfunction in multiple

235 aspects of the memory T cell response which may inform treatment and/or vaccination options

236 down the line.

237 **Discussion**

238 COVID-19 is well-recognized as a multi-organ disease with long-term sequelae
239 associated with neurological disease. PASC has been reported in up to 87% of those hospitalized
240 with SARS-CoV-2 pneumonia and in up to 40% of those with mild disease who do not require
241 hospitalization (Havervall et al., 2021; Hirschtick et al., 2021; Mahase, 2020). SARS-CoV-2
242 vaccines have decreased the rates of SARS-CoV-2 infection and mortality in unexposed
243 individuals, but it is not clear that vaccines help to ameliorate long-COVID symptoms in
244 previously infected individuals (Arnold et al., 2021) and thus further study is needed to inform
245 treatment options. Long-term sequelae after other coronavirus infections can persist for years
246 (Ahmed et al., 2020); therefore, it is important to specifically characterize SARS-CoV-2-specific
247 immune responses in long-COVID patients. Most studies on effector and memory T cell
248 responses to SARS-CoV-2 have focused on acute infection or healthy convalescents as opposed
249 to those with long-COVID (Rodda et al., 2021; Sekine et al., 2020; Weiskopf et al., 2020). We
250 aimed to fill this knowledge gap and determine whether and how T cell phenotype and function
251 differ in patients with neuro-PASC and healthy COVID-19 convalescents.

252 Clinically, neuro-PASC resembles myalgic encephalomyelitis/chronic fatigue syndrome
253 (ME/CFS), which many patients report as a post-viral infectious complication (Rasa et al., 2018).
254 The causes of ME/CFS remain elusive, and the underlying mechanisms of neuro-PASC remain
255 similarly unknown. It is possible that direct infection of the brain is responsible for neuro-PASC
256 symptoms. It is believed that SARS-CoV-2 gains entry into the central nervous system through
257 the olfactory bulb and has been shown to infect neurons in vitro, which is supported by findings
258 of viral protein expression in cortical neurons from post-mortem autopsies (Klingenstein et al.,
259 2020; Song et al., 2021). However, another study was unable to find any evidence of SARS-

260 CoV-2 in the brains of 4 patients with neurological symptoms during acute infection (Kantonen
261 et al., 2020), suggesting that infection of the nervous system may be transient. Another study of
262 acutely infected neuro-COVID patients did not find any SARS-CoV-2 RNA present in the CSF,
263 though they did identify enhanced presence of exhausted T cells and dedifferentiated monocytes
264 (Heming et al., 2021). However, all of these prior studies were conducted on patients with acute
265 SARS-CoV-2 infection as opposed to neuro-PASC, and thus mechanisms for neurological
266 dysfunction may differ. As lumbar punctures or brain biopsies are not indicated in neuro-PASC
267 outpatients, reproducing the above study results in outpatient populations will not be possible.
268 Additional hypotheses for neuro-PASC pathogenesis include a contribution of autoimmune
269 mechanisms which is suggested by the skewed ratio of females to males affected, similar to that
270 seen in rheumatoid arthritis or systemic lupus erythematosus (Chakravarty et al., 2007;
271 Myasoedova et al., 2010), as well as the possibility of persistent SARS-CoV-2 infection in the
272 periphery (Al-Aly et al., 2021). Much of our findings on the SARS-CoV-2 T cell response in
273 neuro-PASC patients supports this latter hypothesis.

274 Ag-specific IFN-γ and IL-2 production was similar between CN and CC groups in
275 response to stimulation by different SARS-CoV-2 Spike peptide pools (Fig. 2A-B). However, T
276 cells from CN patients retained high IFN-γ responses to all N- and M-peptide pools tested, while
277 CC subjects had a reactivity limited to N1 and N2 peptide pools with little IFN-γ production in
278 response to M pools (Fig. 2C-D). The presence of an immunodominance hierarchy in CC
279 subjects is the expected outcome of an effective memory response to SARS-CoV-2 infection.
280 Studies have shown that while a primary $CD4^+$ or $CD8^+$ T cell response to influenza A or LCMV
281 infection is highly diverse and contains T cells reactive to many viral proteins and epitopes, the
282 memory response preferentially contains T cells responding to specific immunodominant viral

283 antigens (Sant et al., 2018; Tebo et al., 2005). This effect is more pronounced in the $CD8^+$ T cell
284 compartment where memory responses are dependent on the ability of dendritic cells to present
285 viral antigen (Crowe et al., 2003) or on antigen availability (Henrickson et al., 2013). The
286 evident lack of a narrow and targeted IFN-γ response to N- and M-peptides in CN patients thus
287 suggests that they are unable to effectively generate a memory response to SARS-CoV-2.
288 Though there were no differences observed in the magnitude or specificity of the IFN-γ response
289 to SARS-CoV-2 Spike peptides, this is somewhat expected as memory T cell responses to Spike
290 protein remain diverse after both infection (Grifoni et al., 2020) and vaccination (Alter et al.,
291 2021). It is additionally not surprising that differences in reactivity were observed for IFN-γ and
292 not IL-2 T cell responses between CN and CC groups (Fig. 2B, E-F). Studies have demonstrated
293 that while Ag-specific T cells produce IL-2 as a proliferation factor, IFN-γ production is largely
294 confined to the memory T cell population (Anthony et al., 2012), which is largely where we see
295 differences in activation and reactivity between groups (Fig. 4).

296 Antibody production is a key outcome measure after SARS-CoV-2 infection, Tfh cell
297 activation can inform the effectiveness of an antibody response. Stimulation with SARS-CoV-2
298 N peptides activated Tfh cells in CN but not CC subjects, while the opposite trend was found
299 with M pool stimulation (Fig. 3A-B). Tfh cell activation is crucial to the establishment of
300 germinal centers in secondary lymphoid organs, ultimately resulting in B cell maturation into
301 long-lived plasma cells that can continuously produce class-switched, high-affinity antibodies
302 (Good-Jacobson and Shlomchik, 2010). Studies have demonstrated that the magnitude of the Tfh
303 cell response is dependent on the amount of antigen available and directly correlates with the
304 magnitude of the B cell response (Baumjohann et al., 2013). Indeed, the same CN patients with
305 high N-specific Tfh cell activation also displayed anti-N IgG titers significantly greater than CC

306 subjects (Fig. 3E) despite the fact that we obtained their samples more than 6 months on average
307 after acute infection. Altogether, these findings are consistent with the presence of a persisting
308 nucleocapsid antigen reservoir resulting in enhanced N-specific Tfh cell activation in CN
309 patients. Clinical reports have identified cases of persistent SARS-CoV-2 infection in the
310 nasopharynx lasting up to 63 days (Bennasrallah et al., 2020) and many patients re-tested RT-
311 PCR+ for SARS-CoV-2 up to 38 days post-discharge (Dao et al., 2021). Though many of our
312 CN patients have not re-tested RT-PCR+ by nasal swab (data not shown), others have yet to be
313 tested. The nasopharynx is not the only possible testing site, however, as there are numerous
314 studies showing that infectious SARS-CoV-2 particles can be detected in fecal matter and can
315 persist for up to 70 days post-symptom onset (Tian et al., 2020; van Doorn et al., 2020).
316 Gastrointestinal symptoms also did not have to be present in order to test RT-PCR+ for SARS-
317 CoV-2 in stool samples (Chen et al., 2020). Thus, it is possible that the gut may also act as a
318 reservoir for persistent SARS-CoV-2 infection which leads to aberrant T cell responses and the
319 development of neuro-PASC.

320 Effective generation of T cell memory responses is crucial to protect against future
321 infections with the same pathogen. $CD8^+$ TEM cells from CC subjects retained high levels of
322 activation to all S, N, and M pools assayed while CN patients displayed very little TEM
323 activation (Fig. 4A-B), suggestive of aberrant memory T cell function. Studies on convalescents
324 from the original SARS-CoV epidemic of 2002-03 found that the majority of Ag-specific $CD8^+$
325 memory T cells were TEM, and these persisted up to 4 years after infection (Channappanavar et
326 al., 2014). Sterilizing immunity can be a precondition for the development and maintenance of
327 memory T cells because high levels of foreign antigen favor the generation of short-lived
328 effector cells (Mueller et al., 2013), which is why chronic infections often limit the formation

329 and/or function of memory T cells (Wherry, 2011). In fact, chronic LCMV infection in mice
330 induced aberrantly functioning Ag-specific memory $CD8^+$ T cells requiring the presence of viral
331 peptide rather than simply the homeostatic cytokines IL-7 and IL-15 to proliferate (Shin et al.,
332 2007; Wherry et al., 2004). The inability of $CD8^+$ TEM to become activated by antigenic
333 stimulation in CN patients is thus suggestive of a chronic infection state wherein viral antigen
334 can persist but limits the formation of $CD8^+$ T cell memory. It is also possible that chronic
335 SARS-CoV-2 infection in CN patients leads to memory T cell exhaustion, as shown in chronic
336 HIV and HBV infections in humans (McLane et al., 2019). However, we did not find any
337 differences in the inhibitory marker PD-1 expression on $CD8^+$ memory T cell subsets between
338 CN and CC patients (data not shown).

339 Further providing support to the chronic infection hypothesis in neuro-PASC patients,
340 there was a significant elevation in the $CD8^+$ TEMRA cell population in CN patients over CC or
341 HC groups (Fig. 4C). $CD8^+$ TEMRA cells are a terminally differentiated memory subset that do
342 not traffic through secondary lymphoid organs, and their induction during viral infection can be
343 protective (Tian et al., 2019). Yet, they have also been shown to accumulate during persistent
344 viral infections and contribute to immunosenescence (Derhovanessian et al., 2011). $CD8^+$
345 TEMRA cell reactivity to SARS-CoV-2 peptides was also decreased in CN patients over CC
346 subjects. Functionally, the polarization in granzyme production in S3/4-specific $CD8^+$ TEMRA
347 cells from CC patients (Fig. 4G) suggests higher cytotoxic capacity compared with CN patients
348 and coincides with their higher activation state in Fig. 4E. Ag-specific $CD8^+$ TEMRA cells are
349 expanded and functionally active in people with significant anti-Dengue virus immunity, and this
350 phenotype is seen as a goal for vaccine-induced protection (Tian et al., 2019). We propose that
351 $CD8^+$ TEMRA cells are more expanded but less functionally active in CN subjects over CC as a

352 consequence of inappropriate $CD8^+$ T cell memory formation, which is lacking in multiple T cell
353 subsets for neuro-PASC patients.

354 We also showed that $CD8^+$ T cells from CC subjects skewed towards TNF-α production
355 after S pool stimulation compared with CN patients. Comparatively, CN patients displayed
356 significantly more IL-6 production from S-specific $CD8^+$ T cells (Fig. 4F). Vaccination against
357 the intracellular pathogen *Shigella flexneri* showed that polyfunctional TNF-α-producing $CD8^+$
358 TEM were an important correlate of protection (Toapanta et al., 2018). Despite multiple reports
359 indicating that enhanced TNF-α production is correlated with worse COVID-19 outcomes (Karki
360 et al., 2020, 2021; Pedersen and Ho, 2020), we speculate that Ag-specific TNF-α production is
361 protective in our model system because we are looking at chronically and not acutely infected
362 CN patients. In contrast, IL-6 is known to suppress T_H1 differentiation (Diehl et al., 2000) and
363 can promote pathogen survival and exacerbate clinical disease during the original SARS-CoV
364 infection (Channappanavar and Perlman, 2017). Indeed, studies in severely ill, hospitalized
365 COVID-19 patients demonstrated that high serum levels of IL-6 significantly correlated with
366 poor clinical outcome (Weiskopf et al., 2020). These data suggest a role for enhanced IL-6
367 production by $CD8^+$ T cells in the pathogenesis of neuro-PASC, and open new avenues of
368 research for the treatment of long-COVID through limiting IL-6 activity.

369 Clinically, neuro-PASC patients reported significantly elevated levels of anxiety,
370 depression, fatigue, sleep disturbance and pain as well as decreased physical function compared
371 with healthy convalescents (Fig. 1C). The severity of these deficits was highly correlated with
372 Ag-specific enhancements in polyfunctionality and decreases in polarization of various memory
373 T cell subsets (Fig. 5, S7). It is possible that T cell function contributes to the genesis and
374 persistence of some of these symptoms. Studies in rodents have shown that T cell activation and

375 function can affect the severity of pain and analgesia (Rosen et al., 2019; Sorge et al., 2015).
376 Indeed, pain is a common hallmark of chronic viral infection (Addis et al., 2020) and recognized
377 among post-COVID sequelae (Kemp et al., 2020); it might follow then that aberrant T cell
378 activation can associate with high pain scores. Additionally, reports have shown that
379 transcriptional programs in immunity and inflammation were differentially regulated in $CD4^+$ T
380 cells from patients with depression compared with healthy controls (Wang et al., 2015). T_{reg} cells
381 may also decrease depressive behavior through negative regulation of inflammation (Miller,
382 2010), and CN patients do display elevated T_H1-type cytokine production to S pool stimulation
383 (Fig. 2, 6) while not displaying any compensatory upregulation in T_{reg} total numbers or function
384 (data not shown). T cell-derived cytokines can also impact learning and memory. Studies in
385 mouse models of West Nile and Zika viral encephalitis have demonstrated that IFN-γ production
386 from $CD8^+$ T cells in the brain is responsible for neuronal apoptosis and spatial learning deficits
387 (Garber et al., 2019). Thus, there is a precedent for correlating T cell function with cognitive
388 deficits, pain, or depression. Ag-specific cytokine signatures associated with the severity of
389 cognitive and quality of life deficits in neuro-PASC patients may therefore provide some
390 predictive value in terms of clinical outcomes.

391 Preliminary reports showed that the Pfizer mRNA vaccine could elicit a T cell response 7
392 days after completion of the full prime-boost protocol (Sahin et al., 2020), but until our studies
393 there has been no data on longitudinal T cell responses primed by vaccination and how these
394 vary between groups with different types of prior SARS-CoV-2 exposure. Our results
395 demonstrate for the first time that vaccine-elicited immune responses are significantly divergent
396 in neuro-PASC versus healthy COVID convalescents (Fig. 6C-D). CN patients consistently had
397 higher antibody titers after receiving the second dose of the vaccine compared with CC and HC

398 groups, though titers were similar in all groups at 11-15 weeks post-1st dose (Fig. 6C). In
399 contrast, the magnitude of Spike-specific IFN-γ production by T cells remained high in CN
400 patients out to 4 months post-vaccination while not significantly higher than pre-vaccination
401 levels in CC and HC subjects along the same timeline (Fig. 6D). These data suggest that the
402 mRNA vaccines do not induce robust long-term T cell responses in many individuals, regardless
403 of prior COVID exposure, if they are not neuro-PASC patients. Yet, despite vaccines enhancing
404 Spike-specific IFN-γ production in CN T cells, the fact that these responses continue to increase
405 at 15 weeks post-vaccination suggests that CN patients may still have an active SARS-CoV-2
406 infection or a persistent antigen reservoir rather than developing a robust T cell memory
407 response. These results suggest that alternate SARS-CoV-2 vaccines that induce long-lasting
408 memory T cell responses in previously unexposed individuals as well as healthy COVID
409 convalescents are needed in order to mediate long-term protection from infection. Conversely,
410 vaccination may not be indicated for long-COVID patients who might have a persistent infection
411 as it may be ineffective in the absence of viral clearance. Indeed, current clinical guidance from
412 the CDC recommends that vaccination be delayed until 3 months after acute infection in
413 unvaccinated COVID convalescents. Thus, vaccination strategies that include the memory T cell
414 response as a marker for efficacy should be carefully considered. Together, these data show that
415 irregular Tfh responses, broad scale dysfunction in $CD8^+$ T cell memory generation and aberrant
416 T cell responses to vaccination are hallmarks of neuro-PASC and require further study to inform
417 treatment and vaccination strategies across the population.

418 **Limitations of study**

419 One limitation of our study is the relatively small sample size of unvaccinated neuro-
420 PASC patients. This was due to the wide implementation of SARS-CoV-2 vaccines in the

421 Chicago area soon after beginning study enrollment. Another limitation was not being able to
422 control for time of sample collection with respect to date of COVID-19 symptom onset. As it is
423 possible that neuro-PASC could be the result of a persistent infection, further investigations
424 would require testing of potential cryptic reservoirs, including stool samples from CN patients.
425

426 **Materials and Methods**

427 *Ethics Statement*

428 This study was approved by the Northwestern University Institutional Review Board (Koralnik
429 Lab, IRB STU00212583). Informed consent was obtained from all enrolled participants. Samples
430 were de-identified before banking.

431 *Study participants, NIH Toolbox, and PROMIS-57 data collection*

432 We enrolled consenting unvaccinated adult outpatients seen in the Neuro-PASC-19 clinic at
433 Northwestern Memorial Hospital from September 2020-June 2021, including 56 neuro-PASC
434 "long-hauler" patients with documented PCR+ or seropositive IgG results for SARS-CoV-2
435 (CN). In parallel, we recruited 24 unvaccinated healthy COVID convalescents from the
436 surrounding community who tested PCR+ for SARS-CoV-2 but had no lingering neurological
437 symptoms (CC) and 31 healthy controls who tested PCR- for SARS-CoV-2 and were also
438 seronegative for IgG against SARS-CoV-2 Spike RBD. All study subjects remained living
439 throughout the period of observation. Heparinized blood samples were collected one time from
440 each subject at an average of 155-315 days post-symptom onset (as in Fig. 1B). Other
441 demographic information is contained in Fig. 1B. CN patients completed a cognitive function
442 evaluation in the clinic coincident or near the date of their blood sample acquisition with the
443 National Institutes of Health (NIH) Toolbox v2.1 instrument, including assessments of:
444 processing speed (pattern comparison processing speed test); attention and executive memory
445 (inhibitory control and attention test); executive function (dimensional change card sort test); and
446 working memory (list sorting working memory test) (Lai et al., 2011; Weintraub et al., 2013).
447 PROMIS-57 was administered to CN and CC patients an average of 72 days post-sample

448 collection. Both PROMIS-57 and NIH Toolbox results are expressed as T-scores adjusted for
449 age, education, gender, and race/ethnicity with a score of 50 representing the normative
450 mean/median of the US reference population with a standard deviation of 10. Lower cognition T-
451 scores indicate worse performance while higher fatigue, depression, anxiety, or pain interference
452 T-scores indicate greater symptom severity.

453 *PBMC and plasma collection*

454 30mL of venous blood from study volunteers was collected in blood collection tubes containing
455 sodium heparin from BD Biosciences. Whole blood was layered on top of 15mL of Histopaque
456 1077 (Sigma-Aldrich) in 50mL Leucosep blood separation tubes (Greiner Bio-One) and spun at
457 1000g for 18min at RT. Plasma was collected and stored at -80°C. The PBMC layer was
458 collected and washed 2x in sterile PBS before red blood cell lysis with ACK buffer (Quality
459 Biologicals). PBMCs were used in assays either immediately or frozen down for use in the near
460 term.

461 *SARS-CoV-2 peptide antigens*

462 All S, N and M peptide arrays used in ELISPOT and flow cytometry studies were obtained from
463 BEI Resources, NIAID, NIH: Peptide Array, SARS-Related Coronavirus 2 Spike (S) Protein;
464 NR-52402, Nucleocapsid (N) Protein, NR-52404; Membrane (M) Protein, NR-52403. The S
465 peptide array consisted of 181 peptides of 13-17aa in length and split into 6 sub-pools (S1-S6)
466 containing 30-31 peptides each. The N peptide array consisted of 59 peptides of 13-17aa each
467 split into 3 sub-pools containing 29-30 peptides each. The M peptide array consisted of 31
468 peptides of 12-17aa and split into 3 sub-pools of 10-11 peptides each (Fig. S1). All peptides were

469 dissolved in either sterile H_2O or 50% sterile H_2O-DMSO up to 1mL for a universal 1mg/mL
470 stock concentration. Peptides were used at a final concentration at 2µg/mL in all assays.

471 *IgG Spike RBD and Nucleocapsid ELISA*

472 Antigen-specific total antibody titers were measured by ELISA as described previously (Dangi et
473 al., 2020; Palacio et al., 2020). In brief, 96-well flat-bottom MaxiSorp plates (Thermo Scientific)
474 were coated with 1 µg/ml of Spike RBD for 48 hr at 4°C. Plates were washed three times with
475 wash buffer (PBS + 0.05% Tween 20). Blocking was performed with blocking solution (PBS +
476 0.05% Tween 20 + 2% bovine serum albumin), for 4 hr at room temperature. 6 µl of sera was
477 added to 144 µl of blocking solution in the first column of the plate, 1:3 serial dilutions were
478 performed until row 12 for each sample, and plates were incubated for 60 min at room
479 temperature. Plates were washed three times with wash buffer followed by addition of secondary
480 antibody conjugated to horseradish peroxidase, goat anti-human IgG (H + L) (Jackson
481 ImmunoResearch) diluted in blocking solution (1:1000) and 100 µl/well was added and
482 incubated for 60 min at room temperature. After washing plates three times with wash buffer,
483 100 µl/well of Sure Blue substrate (SeraCare) was added for 1 min. Reaction was stopped using
484 100 µl/well of KPL TMB Stop Solution (SeraCare). Absorbance was measured at 450 nm using
485 a Spectramax Plus 384 (Molecular Devices). SARS-CoV-2 RBD and N proteins used for ELISA
486 were produced at the Northwestern Recombinant Protein Production Core by Dr. Sergii
487 Pshenychnyi using plasmids that were produced under HHSN272201400008C and obtained from
488 BEI Resources, NIAID, NIH: Vector pCAGGS containing the SARS-related coronavirus 2,
489 Wuhan-Hu-1 spike glycoprotein gene (soluble, stabilized), NR-52394 and receptor binding
490 domain (RBD), NR-52309, nucleocapsid gene NR-53507.

491 *Cell stimulation and IFN-γ/IL-2 ELISPOT*

492 Multiscreen-IP plates (Millipore-Sigma) were coated overnight at 4°C with 2μg/mL anti-IFN-γ
493 (clone 1-D1K, Mabtech) or 5μg/mL anti-IL-2 (clone MT2A91/2C95, Mabtech), washed with
494 sterile PBS, and blocked with complete RPMI-10% FBS. PBMC isolated from CN, CC, and HC
495 subjects were used either freshly isolated or after thawing and resting overnight in media
496 containing 10ng/μL recombinant human IL-15 (Peprotech) at 37°C, 5% CO_2. Cells were then
497 plated at a concentration of $2.5x10^5$ cells/well in 100μL of media and stimulated with the
498 indicated antigen mixtures from SARS-CoV-2 at a concentration of 2μg/mL in complete RPMI
499 medium containing 5% human AB serum (Sigma-Aldrich) and 5ng/mL IL-15. Plates were
500 incubated at 37°C, 5% CO_2 for 20 h and washed 5x with dH_2O and PBS-0.05% Tween-20 (PBS-
501 T). 2μg/mL biotinylated IFN-γ (clone 7-B6-1, Mabtech) or 5μg/mL IL-2 (clone MT8G10,
502 Mabtech) diluted in PBS-10% FBS (PBS-F) was added to the respective wells and plates were
503 incubated for 1.5h at RT. Plates were subsequently incubated for 40 minutes at RT in
504 streptavidin-alkaline phosphatase in PBS-F (Jackson ImmunoResearch) was added after washing
505 plates 5x in PBS-T. ELISPOT plates were developed using an Alkaline Phosphatase Conjugate
506 Substrate Kit according to manufacturer's instructions (Bio-Rad Laboratories, Carlsbad, CA).
507 IFN-γ or IL-2-producing cells were quantified using an ImmunoSpot reader (Cellular
508 Technologies, Ltd., Shaker Heights, OH).
509 *Antibodies and Flow Cytometry*

510 Fresh or frozen PBMCs isolated from the indicated patient groups were stimulated with antigen
511 mixtures as above for 20-22h at 37°C, 5% CO_2. For intracellular staining and cytokine detection,
512 the Brefeldin-A Golgi plug (Biolegend) was added at a 1:1000 concentration 2 hours after
513 antigenic stimulation commenced. Cells were washed with PBS-1% BSA after incubation and
514 incubated with the indicated antibodies for surface phenotyping by AIM assay or for intracellular

515 cytokine staining (ICS). Cells from each subject were left unstimulated in medium containing
516 5ng/mL IL-15 ("background") or stimulated in the presence of the indicated antigens. Fixation
517 and permeabilization was performed using Cytofix/Cytoperm (BD Biosciences). Surface staining
518 was done in the dark at 4°C for 30 minutes, while ICS was done in the dark at RT for 45
519 minutes. Flow cytometry was conducted on 2-5x10^5 cells per condition. Data was acquired on a
520 BD FACSymphony Spectral analyzer and analyzed using FlowJo v10 (BD Biosciences) and
521 SPICE-Pestle (Roederer et al., 2011).

522 *Quantification and Statistical Analysis*

523 Statistical tests to determine significance are described in figure legends and conducted largely in
524 Prism (GraphPad). For pie graphs or heatmaps generated using SPICE analysis, statistics were
525 determined by Permutation test following unstimulated background subtraction, with additional
526 thresholding of 0.03% to account for noise, using SPICE-Pestle. *P*-values lower than 0.05 were
527 considered statistically significant. Quantile stratification was performed within group for CN
528 cohort. Clinical data were collected and managed using REDCap electronic data capture tools
529 hosted at Northwestern University Feinberg School of Medicine (Harris et al., 2009). REDCap
530 (Research Electronic Data Capture) is a secure, web-based software platform designed to support
531 data capture for research studies, providing 1) an intuitive interface for validated data capture; 2)
532 audit trails for tracking data manipulation and export procedures; 3) automated export procedures
533 for seamless data downloads to common statistical packages; and 4) procedures for data
534 integration and interoperability with external sources.

535

536

537 **Acknowledgements**

538 We would like to thank the Flow Cytometry Core Facility at the Robert H. Lurie Comprehensive
539 Cancer Center at Northwestern University supported by Cancer Center Support Grant (NCI
540 CA060553) for their assistance in optimizing antibody panels and help with flow cytometry
541 instrumentation. L.V. was supported by a T32 grant T32AR007611 from the Department of
542 Rheumatology, Northwestern University Feinberg School of Medicine. P.P.M. is supported by a
543 grant from the Emerging and Re-Emerging Pathogens Program (EREPP) at Northwestern
544 University, and a grant from the National Institute on Drug Abuse (NIDA, DP2DA051912).

545

546 **Author Contributions**

547 Conceptualization L.V. P.P.M. and I.K; Investigation L.V., B.H., Z.O., P.H.L, and N.P.; Formal
548 Analysis L.V., B.H., E.M.L., P.P.M. and N.P.; Resources L.V., P.P.M., I.K., Data Curation L.V.;
549 Writing L.V. with feedback from all authors; Supervision P.P.M and I.K.; Project Administration
550 L.V.; Funding Acquisition L.V., P.P.M, and I.K.

551

552 **Declaration of Interests**

553 The authors declare no competing interests.

554

555

556

557 **References**

558 Addis, D.R., DeBerry, J.J., and Aggarwal, S. (2020). Chronic Pain in HIV. Mol Pain *16*,
559 1744806920927276.

560 Ahmed, H., Patel, K., Greenwood, D.C., Halpin, S., Lewthwaite, P., Salawu, A., Eyre, L., Breen,
561 A., O'Connor, R., Jones, A.*, et al.* (2020). Long-term clinical outcomes in survivors of severe
562 acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after
563 hospitalisation or ICU admission: A systematic review and meta-analysis. J Rehabil Med *52*,
564 jrm00063.

565 Al-Aly, Z., Xie, Y., and Bowe, B. (2021). High-dimensional characterization of post-acute
566 sequelae of COVID-19. Nature *594*, 259-264.

567 Alter, G., Yu, J., Liu, J., Chandrashekar, A., Borducchi, E.N., Tostanoski, L.H., McMahan, K.,
568 Jacob-Dolan, C., Martinez, D.R., Chang, A.*, et al.* (2021). Immunogenicity of Ad26.COV2.S
569 vaccine against SARS-CoV-2 variants in humans. Nature.

570 Anthony, D.D., Milkovich, K.A., Zhang, W., Rodriguez, B., Yonkers, N.L., Tary-Lehmann, M.,
571 and Lehmann, P.V. (2012). Dissecting the T Cell Response: Proliferation Assays vs. Cytokine
572 Signatures by ELISPOT. Cells *1*, 127-140.

573 Arnold, D.T., Milne, A., Samms, E., Stadon, L., Maskell, N.A., and Hamilton, F.W. (2021).
574 Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute
575 Infection: A Case Series. Ann Intern Med.

576 Baumjohann, D., Preite, S., Reboldi, A., Ronchi, F., Ansel, K.M., Lanzavecchia, A., and
577 Sallusto, F. (2013). Persistent antigen and germinal center B cells sustain T follicular helper cell
578 responses and phenotype. Immunity *38*, 596-605.

579 Bennasrallah, C., Bannour, R., Jlassi, O., Kacem, M., Fredj, M.B., Abroug, H., Zemni, I.,
580 Garrach, B., Bahri, R., Charfeddine, N., *et al.* (2020). Three COVID-19 cases with a long-term
581 viral shedding period in Tunisia. Pan Afr Med J *35*, 117.
582 Center, J.C.R. (2021). Cumulative worldwide Covid-19 cases (Baltimore, MD: Johns Hopkins
583 University of Medicine).
584 Chakravarty, E.F., Bush, T.M., Manzi, S., Clarke, A.E., and Ward, M.M. (2007). Prevalence of
585 adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained
586 using hospitalization data. Arthritis Rheum *56*, 2092-2094.
587 Channappanavar, R., and Perlman, S. (2017). Pathogenic human coronavirus infections: causes
588 and consequences of cytokine storm and immunopathology. Semin Immunopathol *39*, 529-539.
589 Channappanavar, R., Zhao, J., and Perlman, S. (2014). T cell-mediated immune response to
590 respiratory coronaviruses. Immunol Res *59*, 118-128.
591 Chen, H., Hou, J., Jiang, X., Ma, S., Meng, M., Wang, B., Zhang, M., Zhang, M., Tang, X.,
592 Zhang, F., *et al.* (2005). Response of memory CD8+ T cells to severe acute respiratory syndrome
593 (SARS) coronavirus in recovered SARS patients and healthy individuals. J Immunol *175*, 591-
594 598.
595 Chen, Y., Chen, L., Deng, Q., Zhang, G., Wu, K., Ni, L., Yang, Y., Liu, B., Wang, W., Wei, C.,
596 *et al.* (2020). The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med
597 Virol *92*, 833-840.
598 Crowe, S.R., Turner, S.J., Miller, S.C., Roberts, A.D., Rappolo, R.A., Doherty, P.C., Ely, K.H.,
599 and Woodland, D.L. (2003). Differential antigen presentation regulates the changing patterns of
600 CD8+ T cell immunodominance in primary and secondary influenza virus infections. J Exp Med
601 *198*, 399-410.

602 Dao, T.L., Hoang, V.T., and Gautret, P. (2021). Recurrence of SARS-CoV-2 viral RNA in
603 recovered COVID-19 patients: a narrative review. Eur J Clin Microbiol Infect Dis *40*, 13-25.
604 Derhovanessian, E., Maier, A.B., Hahnel, K., Beck, R., de Craen, A.J.M., Slagboom, E.P.,
605 Westendorp, R.G.J., and Pawelec, G. (2011). Infection with cytomegalovirus but not herpes
606 simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in
607 humans. J Gen Virol *92*, 2746-2756.
608 Diehl, S., Anguita, J., Hoffmeyer, A., Zapton, T., Ihle, J.N., Fikrig, E., and Rincon, M. (2000).
609 Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity *13*, 805-815.
610 Duan, Y.Q., Xia, M.H., Ren, L., Zhang, Y.F., Ao, Q.L., Xu, S.P., Kuang, D., Liu, Q., Yan, B.,
611 Zhou, Y.W.*, et al.* (2020). Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19
612 Patients. Curr Med Sci *40*, 618-624.
613 Garber, C., Soung, A., Vollmer, L.L., Kanmogne, M., Last, A., Brown, J., and Klein, R.S.
614 (2019). T cells promote microglia-mediated synaptic elimination and cognitive dysfunction
615 during recovery from neuropathogenic flaviviruses. Nat Neurosci *22*, 1276-1288.
616 Good-Jacobson, K.L., and Shlomchik, M.J. (2010). Plasticity and heterogeneity in the generation
617 of memory B cells and long-lived plasma cells: the influence of germinal center interactions and
618 dynamics. J Immunol *185*, 3117-3125.
619 Goubard, A., Loiez, C., Abe, J., Fichel, C., Herwegh, S., Faveeuw, C., Porte, R., Cayet, D.,
620 Sebbane, F., Penet, S.*, et al.* (2015). Superantigenic Yersinia pseudotuberculosis induces the
621 expression of granzymes and perforin by CD4+ T cells. Infect Immun *83*, 2053-2064.
622 Graham, E.L., Clark, J.R., Orban, Z.S., Lim, P.H., Szymanski, A.L., Taylor, C., DiBiase, R.M.,
623 Jia, D.T., Balabanov, R., Ho, S.U.*, et al.* (2021). Persistent neurologic symptoms and cognitive
624 dysfunction in non-hospitalized Covid-19 "long haulers". Ann Clin Transl Neurol *8*, 1073-1085.

625 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings,
626 S.A., Sutherland, A., Premkumar, L., Jadi, R.S.*, et al.* (2020). Targets of T Cell Responses to
627 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell
628 *181*, 1489-1501 e1415.
629 Haas, E.J., Angulo, F.J., McLaughlin, J.M., Anis, E., Singer, S.R., Khan, F., Brooks, N., Smaja,
630 M., Mircus, G., Pan, K.*, et al.* (2021). Impact and effectiveness of mRNA BNT162b2 vaccine
631 against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a
632 nationwide vaccination campaign in Israel: an observational study using national surveillance
633 data. Lancet *397*, 1819-1829.
634 Halpin, S.J., McIvor, C., Whyatt, G., Adams, A., Harvey, O., McLean, L., Walshaw, C., Kemp,
635 S., Corrado, J., Singh, R.*, et al.* (2021). Postdischarge symptoms and rehabilitation needs in
636 survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol *93*, 1013-1022.
637 Hampshire, A., Trender W., Chamberlain SR, Jolly AE, Grant JE, Patrick F, Mazibuko N,
638 Williams S, Barnaby JM, Hellyer H, Mehta MA. (2021). Cognitive deficits in people who have
639 recovered from COVID-19. EClinicalMedicine.
640 Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., and Conde, J.G. (2009). Research
641 electronic data capture (REDCap)--a metadata-driven methodology and workflow process for
642 providing translational research informatics support. J Biomed Inform *42*, 377-381.
643 Havervall, S., Rosell, A., Phillipson, M., Mangsbo, S.M., Nilsson, P., Hober, S., and Thalin, C.
644 (2021). Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19
645 Among Health Care Workers. JAMA *325*, 2015-2016.
646 Heming, M., Li, X., Rauber, S., Mausberg, A.K., Borsch, A.L., Hartlehnert, M., Singhal, A., Lu,
647 I.N., Fleischer, M., Szepanowski, F.*, et al.* (2021). Neurological Manifestations of COVID-19

648 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity *54*,
649 164-175 e166.
650 Henrickson, S.E., Perro, M., Loughhead, S.M., Senman, B., Stutte, S., Quigley, M., Alexe, G.,
651 Iannacone, M., Flynn, M.P., Omid, S.*, et al.* (2013). Antigen availability determines CD8(+) T
652 cell-dendritic cell interaction kinetics and memory fate decisions. Immunity *39*, 496-507.
653 Higgins, V., Sohaei, D., Diamandis, E.P., and Prassas, I. (2020). COVID-19: from an acute to
654 chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci, 1-23.
655 Hirschtick, J.L., Titus, A.R., Slocum, E., Power, L.E., Hirschtick, R.E., Elliott, M.R., McKane,
656 P., and Fleischer, N.L. (2021). Population-based estimates of post-acute sequelae of SARS-CoV-
657 2 infection (PASC) prevalence and characteristics. Clin Infect Dis.
658 Kantonen, J., Mahzabin, S., Mayranpaa, M.I., Tynninen, O., Paetau, A., Andersson, N., Sajantila,
659 A., Vapalahti, O., Carpen, O., Kekalainen, E.*, et al.* (2020). Neuropathologic features of four
660 autopsied COVID-19 patients. Brain Pathol *30*, 1012-1016.
661 Karki, R., Sharma, B.R., Tuladhar, S., Williams, E.P., Zalduondo, L., Samir, P., Zheng, M.,
662 Sundaram, B., Banoth, B., Malireddi, R.K.S.*, et al.* (2020). COVID-19 cytokines and the
663 hyperactive immune response: Synergism of TNF-alpha and IFN-gamma in triggering
664 inflammation, tissue damage, and death. bioRxiv.
665 Karki, R., Sharma, B.R., Tuladhar, S., Williams, E.P., Zalduondo, L., Samir, P., Zheng, M.,
666 Sundaram, B., Banoth, B., Malireddi, R.K.S.*, et al.* (2021). Synergism of TNF-alpha and IFN-
667 gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2
668 Infection and Cytokine Shock Syndromes. Cell *184*, 149-168 e117.
669 Kemp, H.I., Corner, E., and Colvin, L.A. (2020). Chronic pain after COVID-19: implications for
670 rehabilitation. Br J Anaesth *125*, 436-440.

671 Klingenstein, M., Klingenstein, S., Neckel, P.H., Mack, A.F., Wagner, A.P., Kleger, A., Liebau,
672 S., and Milazzo, A. (2020). Evidence of SARS-CoV2 Entry Protein ACE2 in the Human Nose
673 and Olfactory Bulb. Cells Tissues Organs *209*, 155-164.
674 Ladds, E., Rushforth, A., Wieringa, S., Taylor, S., Rayner, C., Husain, L., and Greenhalgh, T.
675 (2020). Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and
676 draft quality principles for services. BMC Health Serv Res *20*, 1144.
677 Lai, J.S., Cella, D., Choi, S., Junghaenel, D.U., Christodoulou, C., Gershon, R., and Stone, A.
678 (2011). How item banks and their application can influence measurement practice in
679 rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil *92*, S20-
680 27.
681 Lam, M.H., Wing, Y.K., Yu, M.W., Leung, C.M., Ma, R.C., Kong, A.P., So, W.Y., Fong, S.Y.,
682 and Lam, S.P. (2009). Mental morbidities and chronic fatigue in severe acute respiratory
683 syndrome survivors: long-term follow-up. Arch Intern Med *169*, 2142-2147.
684 Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y.,
685 Lin, M., Tan, N., Linster, M.*, et al.* (2020). SARS-CoV-2-specific T cell immunity in cases of
686 COVID-19 and SARS, and uninfected controls. Nature *584*, 457-462.
687 Li, Y.C., Bai, W.Z., and Hashikawa, T. (2020). The neuroinvasive potential of SARS-CoV2 may
688 play a role in the respiratory failure of COVID-19 patients. J Med Virol *92*, 552-555.
689 Liguori, C., Pierantozzi, M., Spanetta, M., Sarmati, L., Cesta, N., Iannetta, M., Ora, J., Mina,
690 G.G., Puxeddu, E., Balbi, O.*, et al.* (2020). Subjective neurological symptoms frequently occur
691 in patients with SARS-CoV2 infection. Brain Behav Immun *88*, 11-16.
692 Mahase, E. (2020). Covid-19: What do we know about "long covid"? BMJ *370*, m2815.

693 McLane, L.M., Abdel-Hakeem, M.S., and Wherry, E.J. (2019). CD8 T Cell Exhaustion During
694 Chronic Viral Infection and Cancer. Annu Rev Immunol *37*, 457-495.
695 McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J.,
696 Peter, L., Atyeo, C., Zhu, A.*, et al.* (2021). Correlates of protection against SARS-CoV-2 in
697 rhesus macaques. Nature *590*, 630-634.
698 Meckiff, B.J., Ramirez-Suastegui, C., Fajardo, V., Chee, S.J., Kusnadi, A., Simon, H.,
699 Eschweiler, S., Grifoni, A., Pelosi, E., Weiskopf, D.*, et al.* (2020). Imbalance of Regulatory and
700 Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. Cell *183*, 1340-1353 e1316.
701 Miller, A.H. (2010). Depression and immunity: a role for T cells? Brain Behav Immun *24*, 1-8.
702 Mockus, T.E., Ren, H.M., Shwetank, and Lukacher, A.E. (2019). To Go or Stay: The
703 Development, Benefit, and Detriment of Tissue-Resident Memory CD8 T Cells during Central
704 Nervous System Viral Infections. Viruses *11*.
705 Muecksch, F., Wise, H., Batchelor, B., Squires, M., Semple, E., Richardson, C., McGuire, J.,
706 Clearly, S., Furrie, E., Greig, N.*, et al.* (2021). Longitudinal Serological Analysis and
707 Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. J Infect Dis
708 *223*, 389-398.
709 Mueller, S.N., Gebhardt, T., Carbone, F.R., and Heath, W.R. (2013). Memory T cell subsets,
710 migration patterns, and tissue residence. Annu Rev Immunol *31*, 137-161.
711 Myasoedova, E., Crowson, C.S., Kremers, H.M., Therneau, T.M., and Gabriel, S.E. (2010). Is
712 the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-
713 2007. Arthritis Rheum *62*, 1576-1582.
714 Pedersen, S.F., and Ho, Y.C. (2020). SARS-CoV-2: a storm is raging. J Clin Invest *130*, 2202-
715 2205.

716 Peng, Y., Mentzer, A.J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T.,
717 Supasa, P., Liu, C., *et al.* (2020). Broad and strong memory CD4(+) and CD8(+) T cells induced
718 by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol *21*, 1336-
719 1345.
720 Petersen, M.S., Kristiansen, M.F., Hanusson, K.D., Danielsen, M.E., B, A.S., Gaini, S., Strom,
721 M., and Weihe, P. (2020). Long COVID in the Faroe Islands - a longitudinal study among non-
722 hospitalized patients. Clin Infect Dis.
723 Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Perez
724 Marc, G., Moreira, E.D., Zerbini, C., *et al.* (2020). Safety and Efficacy of the BNT162b2 mRNA
725 Covid-19 Vaccine. N Engl J Med *383*, 2603-2615.
726 Rasa, S., Nora-Krukle, Z., Henning, N., Eliassen, E., Shikova, E., Harrer, T., Scheibenbogen, C.,
727 Murovska, M., Prusty, B.K., and European Network on, M.C. (2018). Chronic viral infections in
728 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med *16*, 268.
729 Rodda, L.B., Netland, J., Shehata, L., Pruner, K.B., Morawski, P.A., Thouvenel, C.D., Takehara,
730 K.K., Eggenberger, J., Hemann, E.A., Waterman, H.R., *et al.* (2021). Functional SARS-CoV-2-
731 Specific Immune Memory Persists after Mild COVID-19. Cell *184*, 169-183 e117.
732 Roederer, M., Nozzi, J.L., and Nason, M.C. (2011). SPICE: exploration and analysis of post-
733 cytometric complex multivariate datasets. Cytometry A *79*, 167-174.
734 Rosen, S.F., Ham, B., Haichin, M., Walters, I.C., Tohyama, S., Sotocinal, S.G., and Mogil, J.S.
735 (2019). Increased pain sensitivity and decreased opioid analgesia in T-cell-deficient mice and
736 implications for sex differences. Pain *160*, 358-366.

737 Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L.M., Vormehr, M., Baum, A.,
738 Pascal, K., Quandt, J., Maurus, D.*, et al.* (2020). COVID-19 vaccine BNT162b1 elicits human
739 antibody and TH1 T cell responses. Nature *586*, 594-599.
740 Sant, A.J., DiPiazza, A.T., Nayak, J.L., Rattan, A., and Richards, K.A. (2018). CD4 T cells in
741 protection from influenza virus: Viral antigen specificity and functional potential. Immunol Rev
742 *284*, 91-105.
743 Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Stralin, K., Gorin, J.B., Olsson, A.,
744 Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S.*, et al.* (2020). Robust T Cell
745 Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell *183*, 158-
746 168 e114.
747 Shin, H., Blackburn, S.D., Blattman, J.N., and Wherry, E.J. (2007). Viral antigen and extensive
748 division maintain virus-specific CD8 T cells during chronic infection. J Exp Med *204*, 941-949.
749 Sledzinska, A., Vila de Mucha, M., Bergerhoff, K., Hotblack, A., Demane, D.F., Ghorani, E.,
750 Akarca, A.U., Marzolini, M.A.V., Solomon, I., Vargas, F.A.*, et al.* (2020). Regulatory T Cells
751 Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4(+) T
752 Cells. Immunity *52*, 151-166 e156.
753 Song, E., Zhang, C., Israelow, B., Lu-Culligan, A., Prado, A.V., Skriabine, S., Lu, P., Weizman,
754 O.E., Liu, F., Dai, Y.*, et al.* (2021). Neuroinvasion of SARS-CoV-2 in human and mouse brain. J
755 Exp Med *218*.
756 Sorge, R.E., Mapplebeck, J.C., Rosen, S., Beggs, S., Taves, S., Alexander, J.K., Martin, L.J.,
757 Austin, J.S., Sotocinal, S.G., Chen, D.*, et al.* (2015). Different immune cells mediate mechanical
758 pain hypersensitivity in male and female mice. Nat Neurosci *18*, 1081-1083.

759 Syed, A., Khan, A., Gosai, F., Asif, A., and Dhillon, S. (2020). Gastrointestinal pathophysiology
760 of SARS-CoV2 - a literature review. J Community Hosp Intern Med Perspect *10*, 523-528.
761 Tang, E., Ekundayo, O., Peipert, J.D., Edwards, N., Bansal, A., Richardson, C., Bartlett, S.J.,
762 Howell, D., Li, M., Cella, D.*, et al.* (2019). Validation of the Patient-Reported Outcomes
763 Measurement Information System (PROMIS)-57 and -29 item short forms among kidney
764 transplant recipients. Qual Life Res *28*, 815-827.
765 Tebo, A.E., Fuller, M.J., Gaddis, D.E., Kojima, K., Rehani, K., and Zajac, A.J. (2005). Rapid
766 recruitment of virus-specific CD8 T cells restructures immunodominance during protective
767 secondary responses. J Virol *79*, 12703-12713.
768 Tian, Y., Babor, M., Lane, J., Schulten, V., Patil, V.S., Seumois, G., Rosales, S.L., Fu, Z.,
769 Picarda, G., Burel, J.*, et al.* (2017). Unique phenotypes and clonal expansions of human CD4
770 effector memory T cells re-expressing CD45RA. Nat Commun *8*, 1473.
771 Tian, Y., Babor, M., Lane, J., Seumois, G., Liang, S., Goonawardhana, N.D.S., De Silva, A.D.,
772 Phillips, E.J., Mallal, S.A., da Silva Antunes, R.*, et al.* (2019). Dengue-specific CD8+ T cell
773 subsets display specialized transcriptomic and TCR profiles. J Clin Invest *129*, 1727-1741.
774 Tian, Y., Rong, L., Nian, W., and He, Y. (2020). Review article: gastrointestinal features in
775 COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther *51*, 843-851.
776 Toapanta, F.R., Bernal, P.J., Kotloff, K.L., Levine, M.M., and Sztein, M.B. (2018). T cell
777 mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD
778 1208S in humans. J Transl Med *16*, 61.
779 van Doorn, A.S., Meijer, B., Frampton, C.M.A., Barclay, M.L., and de Boer, N.K.H. (2020).
780 Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-
781 oral transmission. Aliment Pharmacol Ther *52*, 1276-1288.

782 Van Elslande, J., Oyaert, M., Ailliet, S., Van Ranst, M., Lorent, N., Vande Weygaerde, Y.,
783 Andre, E., Lagrou, K., Vandendriessche, S., and Vermeersch, P. (2021). Longitudinal follow-up
784 of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after
785 infection. J Clin Virol *136*, 104765.
786 Vehar, S., Boushra, M., Ntiamoah, P., and Biehl, M. (2021). Post-acute sequelae of SARS-CoV-
787 2 infection: Caring for the 'long-haulers'. Cleve Clin J Med *88*, 267-272.
788 Wang, T., Ji, Y.L., Yang, Y.Y., Xiong, X.Y., Wang, I.M., Sandford, A.J., Liang, Z.A., and He,
789 J.Q. (2015). Transcriptomic profiling of peripheral blood CD4(+) T-cells in asthmatics with and
790 without depression. Gene *565*, 282-287.
791 Weintraub, S., Dikmen, S.S., Heaton, R.K., Tulsky, D.S., Zelazo, P.D., Bauer, P.J., Carlozzi,
792 N.E., Slotkin, J., Blitz, D., Wallner-Allen, K.*, et al.* (2013). Cognition assessment using the NIH
793 Toolbox. Neurology *80*, S54-64.
794 Weiskopf, D., Schmitz, K.S., Raadsen, M.P., Grifoni, A., Okba, N.M.A., Endeman, H., van den
795 Akker, J.P.C., Molenkamp, R., Koopmans, M.P.G., van Gorp, E.C.M.*, et al.* (2020). Phenotype
796 and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory
797 distress syndrome. Sci Immunol *5*.
798 Wherry, E.J. (2011). T cell exhaustion. Nat Immunol *12*, 492-499.
799 Wherry, E.J., Barber, D.L., Kaech, S.M., Blattman, J.N., and Ahmed, R. (2004). Antigen-
800 independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad
801 Sci U S A *101*, 16004-16009.

802

803 **Figure Legends**

804 **Figure 1: Study design and clinical data**

805 A.) Flow chart describing patient populations and experimental assays for each sample. B.) Table
806 showing patient demographics and neurologic symptoms. C.) PROMIS-57 patient reported
807 survey T scores for CN (n=36) and CC (n=13) groups. D.) NIH Toolbox cognitive T scores for
808 CN (n=43). Horizontal black line represents the U.S. national average T score of 50; p values
809 relative to US national average by one sample Wilcoxon signed rank test. *p<0.05, ***p<0.005,
810 ****p<0.0001 by two-tailed Student's t test.

811 **Figure 2: Neuro-PASC long-haulers display altered reactivity to SARS-CoV-2 N and M**
812 **peptides compared to healthy convalescents.**

813 A-B.) CN (PCR+ or seropositive neuro-PASC) and CC (PCR+ or seropositive healthy COVID
814 convalescent) groups display similar IFN-γ and IL-2 responses to peptides from SARS-CoV-2
815 Spike protein by ELISPOT. C-D.) CN samples show significantly enhanced IFN-γ responses to
816 the N3 peptide pool (C) and to the M1 and M3 peptide pools (D) compared with CC or healthy
817 controls. E-F.) N- and M- specific IL-2 production did not significantly differ between patient
818 subgroups. G.) Spike RBD IgG endpoint titer quantification for CN, CC, and HC groups. LOD is
819 limit of detection. Data representative of 10 experiments with all conditions plated in duplicate.
820 *p<0.05, **p<0.01, ***p<0.005, ****p<0.0001 by two-way ANOVA with Tukey's posttest.

821 **Figure 3: N-specific CD4$^+$ Tfh cells are more activated and S-specific CD4$^+$ T cells display**
822 **enhanced polyfunctional granzyme production in neuro-PASC long-haulers.**

823 A.) FACS plots show that Ag-specific CD4 Tfh from CN patients are more highly activated in
824 response to N peptide pool stimulation compared with CC or HC, but less activated by M
825 peptides. B). Quantification of AIM$^+$ Tfh cell activation. C-D.) N- and M-specific AIM$^+$ Tfh cell

826 percentages plotted by time sample obtained post-infection for CN and CC. No correlation was
827 found between these parameters. E.) Anti-SARS-CoV-2 nucleocapsid IgG endpoint titers for
828 CN, CC, and HC subjects shown in 3D. CN patients display significantly elevated anti-N IgG
829 titers compared with CC subjects. F.) Pie graphs show $CD4^+$ T cells from CC patients have
830 enhanced production of granzymes A, B, & M compared with CN or HC subjects in response to
831 SARS-CoV-2 Spike protein. G.) Heatmap quantifying polyfunctionality in different categories of
832 cytokine production between groups. CC subjects produced 2-fold more granzymes A/B/M than
833 CN patients. Data combined from 6 independent experiments with CN n=35, CC n=11, and HC
834 n=9. *$p<0.05$ using one-way ANOVA with Bonferroni's posttest (B) or a Permutation test (E).
835 All pie graphs are showing data after subtracting background (unstimulated condition).

836 **Figure 4: Neuro-PASC long-haulers have decreased $CD8^+$ memory T cell activation and**
837 **function compared with healthy convalescents.**

838 A.) Selected FACS plots showing CD8 TEM cells are less activated in CN vs. CC groups after S
839 and N peptide pool stimulation. B.) Quantification of AIM+ CD8 TEM cells after SARS-CoV-2
840 peptide stimulation. C.) $CD8^+$ TEMRA cells accumulate significantly in PBMC from CN
841 subjects compared with CC or HC. D.) $CD8^+$ TEMRA cells from CN patients are less activated
842 by S3/4 and N pools compared with those from CC subjects. E.) Quantification of AIM^+ $CD8^+$
843 TEMRA cells from D. F.) Pie charts demonstrating that S3/4-specific $CD8^+$ TEM are polarized
844 to produce more TNF-α in CC group while those from CN patients produce significantly more
845 IL-6. G.) $CD8^+$ TEMRA from CC patients are polarized towards category 2 cytokine production
846 in response to S3/4 stimulation compared with CN subjects. Black lines demonstrate boundaries
847 of category 2 cytokine production in each group. Data combined from 5 independent
848 experiments with n=35 CN, n=11 CC. *$p<0.05$, **$p<0.01$ using two-tailed Student's t test with

849 Welch's correction (B, C, E) or permutation test (F, G). All pie graphs are showing data after
850 subtracting background (unstimulated condition).

851 **Figure 5: Clinical measures of cognitive dysfunction and depression correlate with altered**
852 **$CD8^+$ memory T cell function in neuro-PASC long-haulers.**

853 A.) Higher T cell responses to N pool stimulation are positively correlated with high pain scores
854 in CN patients. B.) A positive trend exists between elevated N-specific IFN-γ production and
855 higher depression scores in CN patients. C.) CN patients scoring high on pain interference have
856 Spike-specific $CD8^+$ T cells producing more IL-6 than those scoring low. D.) Heatmap showing
857 CN with low pain scores have Spike-specific $CD8^+$ T cells producing significantly more
858 granzymes A or B than those reporting high pain levels. E.) Pie graph to demonstrate that CN
859 patients in Q4 for depression have significantly enhanced production of granzymes A/B/M
860 compared with patients with low depression scores. F.) Heatmap demonstrating that CN patients
861 with high depression scores had Spike-specific $CD8^+$ TEM producing 3-fold higher levels of
862 granzymes A, B, and M or perforin than those scoring low on depression. G.) Spike-specific
863 $CD8^+$ TCM from CN patients with high scores for executive function are more polarized to
864 produce granzymes A/B/M compared with CN patients from Q1. H.) Heatmap showing Spike-
865 specific $CD8^+$ TCM in Q1 CN patients are more polyfunctional and produce 8-10x more
866 granzymes A/B/M and perforin than those in Q4. Data representative of 5 independent
867 experiments with n=8-9/quartile. All pie graphs showing Ag-specific cytokine production are
868 background subtracted (unstimulated conditions). *$p<0.05$, **$p<0.01$, ****$p<0.001$ using
869 Permutation tests.

870

871 **Figure 6: Spike-specific T cell responses wane within 4 months after vaccination in CC and**
872 **HC subjects while remaining high in CN patients over time.**

873 A.) Vaccine study visit timeline. V0 was obtained before the first dose of either Pfizer or
874 Moderna mRNA vaccines. V1 and V2 were conducted 3 weeks after the first and second doses,
875 respectively. B.) Vaccine study subject demographics. C.) Longitudinal anti-Spike RBD IgG
876 responses from V0-V4 across groups. Antibody titers are highest in CN patients and wane most
877 quickly in HC subjects. D.) IFN-γ production from Spike-specific T cells do not significantly
878 increase in CC and HC groups while remaining high in CN up to V4 post-vaccination. Total S-
879 specific IFN-γ SFU calculated by averaging responses from each sub-pool for each participant
880 (data in Fig. S9). Data combined from 10 individual experiments with all ELISA conditions done
881 in triplicate and all ELISPOT conditions plated in duplicate. *$p<0.05$, **$p<0.01$, ***$p<0.005$,
882 ****$p<0.0001$ by two-way ANOVA with Tukey's posttest or by two-tailed Student's t test.

883

A.



B.

Patient Demographics	CN	CC	HC
Participants	56	24	31
Sex	38F, 18M	16F, 8M	19F, 12M
Race/Ethnicity	39 White 9 Hispanic 4 Asian 4 Black	15 White 6 Hispanic 3 Asian	11 White 5 Hispanic 13 Asian 2 Black
Hospitalization (%)	8 (14.3)	1 (4.2)	0 (0)
Days post-symptom onset (range)	193.4 (20-407)	155.0 (44-458)	NA
Neurologic symptoms (%)	56 (100)	0 (0)	0 (0)
Brain Fog	49 (87.5		
Fatigue	46 (82.1)		
Headache	41 (73.2)		
Dizziness	33 (58.9)		
Anosmia	35 (62.5)		
Dysgeusia	33 (58.9)		
Myalgias	34 (60.7)		

C.



D.



Figure 1


A.
IFN-γ
SFU/10^6 PBMC
CN (n=37)
CC (n=13)
HC (n=11)
S1 S2 S3 S4 S5 S6 S1 S2 S3 S4 S5 S6 S1 S2 S3 S4 S5 S6
Spike Pools
B.
IL-2
SFU/10^6 PBMC
CN (n=35)
CC (n=13)
HC (n=13)
S1 S2 S3 S4 S5 S6 S1 S2 S3 S4 S5 S6 S1 S2 S3 S4 S5 S6
Spike Pools
C.
IFN-γ
SFU/10^6 PBMC
CN (n=38)
CC (n=14)
HC (n=7)
N1 N2 N3 N1 N2 N3 N1 N2 N3
Nucleocapsid Pools
D.
IFN-γ
SFU/10^6 PBMC
p=0.056
M1 M2 M3 M1 M2 M3 M1 M2 M3
Membrane Pools
E.
IL-2
SFU/10^6 PBMC
CN (n=37)
CC (n=14)
HC (n=5)
N1 N2 N3 N1 N2 N3 N1 N2 N3
Nucleocapsid Pools
F.
IL-2
SFU/10^6 PBMC
M1 M2 M3 M1 M2 M3 M1 M2 M3
Membrane Pools
G.
SARS-CoV-2 RBD IgG titer
ns
LoD
CN
CC
HC
-ctrl
(pre-2019)

Figure 2


A.
Tfh
Unstim
N pool
M pool
CN
CC
HC
CD134-APC-Cy7
CD137-APC
B.
Tfh
S1/2 pool
S3/4 pool
S5/6 pool
N pool
M pool
%AIM+ CD4 TFh cells
CN (n=20)
CC (n=11)
HC (n=11)
p=0.053
C.
N pool stimulation
M pool stimulation
CN (n=19)
p=0.11
R²=0.15
p=0.45
R²=0.03
Days post-symptom onset
D.
CC (n=11)
p=0.57
R²=0.07
p=0.67
R²=0.09
E.
anti-N IgG endpoint titer
LoD
ns
F.
Total CD4+ T cells
S3/4 pool
Arc Legend
GZA+
GZB+
GZM+
IL-6+
Perforin+
TNF-α+
Pie Legend
GZA
GZB
GZM
IL-6
Perforin
TNF-α
G.
Total CD4+ T cells
S3/4 pool stimulation
Pie Legend

Figure 3


A.
CD8+ TEM
Unstim
S3/4 pool
N pool
CN
CC
HC
CD69-BB700
CD137-BUV661
B.
CD8+ TEM
S1/2 pool
S3/4 pool
S5/6 pool
N pool
M pool
%AIM+CD8 TEM cells
CN (n=41)
CC (n=19)
HC (n=14)
C.
CD8+ TEMRA%
%CD8+CD45RA+ T cells
ns
D.
CD8+ TEMRA
Unstim
S3/4 pool
N pool
E.
CD8+ TEMRA
S3/4 pool
N pool
%AIM+CD8 TEMRA cells
p=0.0536
CN (n=48)
CC (n=14)
HC (n=11)
F.
CN+
CC
S3/4 pool
CD8+ T cells
GZA+
GZB+
GZM+
IL-6+
Perforin+
TNF-α+
G.
CN
CC
S3/4 pool
CD8+ TEMRA
Arc Legend
GZA+
GZB+
GZM+
IL-6+
Perforin+
TNF-α+
Pie Legend
GZA GZB GZM IL-6 Perforin TNF-α
1 + + + - + -
2 + + + - - -
3 + + - - + -
4 + + - - - -
5 + - - - + -
6 - + - + - -
7 - + - - + -
8 - - - + - +

Figure 4


A.
Pain Interference: N pool
SFU/10⁶ PBMC
T score
*p=0.02
R²=0.29
B.
Depression: N pool
SFU/10⁶ PBMC
T score
p=0.11
R²=0.13
C.
Total CD8⁺ T cells
Ag stimulation: Spike
Clinical measurement: Pain Interference
Pain Interference
Q1
Q4
Pie Legend
GZA
GZB
GZM
IL-6
Perforin
TNF-α
***
D.
Total CD8⁺ T, Spike pool
Pain interference
GZA GZB GZM IL-6 Perf TNFα
E.
CD8 TEM
Ag stimulation: Spike pool
Clinical measurement: Depression
Depression
Arc Legend
GZA+
GZB+
GZM+
IL-6+
Perforin+
TNF-α+
Pie Legend
*
F.
CD8 TEM, Spike pool, Depression
Pie Legend
G.
CD8 TCM
Ag stimulation: Spike
Clinical measurement: Attention
Attention
**
H.
CD8 TCM, Spike, Attention

Figure 5

A.



B.

Vaccine Study Demographics	CN	CC	HC
Participants	19	12	20
Mean Age (range)	50.8 (33-70)	29.2 (22-63)	29.9 (22-59)
Sex	13F, 6M	7F, 5M	13F, 7M
Race/Ethnicity	12 White 5 Hispanic 1 Asian 1 Black	8 White 1 Hispanic 3 Asian	8 White 4 Hispanic 7 Asian 1 Black
Vaccine Brand	13 Pfizer 6 Moderna	10 Pfizer 2 Moderna	16 Pfizer 4 Moderna

C.



D.



Figure 6

884